Company Announcement

4 January 2010

Status regarding Novo Nordisk's holding of its own shares (31 December 2009)

In continuation of the company's announcement dated 6 August 2009 concerning a
planned share repurchase programme, and pursuant to Section 204.25 of the New
York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk
A/S (NYSE: NVO) and its wholly-owned affiliates on 31 December 2009 owned
32,137,945 of its own B shares of DKK 1, corresponding to a total nominal value
of DKK 32,137,945 or 5.18% of the total share capital.

In the fourth quarter of 2009 a total of 4,534,767 B shares were repurchased,
and 120,630 B shares were disposed of to employees in connection with employee
incentive programmes.


Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81
countries, and markets its products in 179 countries. Novo Nordisk’s B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol ‘NVO’. For more information,
visitnovonordisk.com <

http://www.novonordisk.com/>.

 For further information please contact:


 Media:                                  Investors:


 Outside North America:                  Outside North America:

 Elin K Hansen                           Mads Veggerby Lausten

 Tel: (+45) 4442 3450                    Tel: (+45) 4443 7919

 ekh@novonordisk.com                     mlau@novonordisk.com
 <mailto:ekh@novonordisk.com>            <mailto:mlau@novonordisk.com>


                                         Kasper Roseeuw Poulsen

                                         Tel: (+45) 4442 4471

                                         krop@novonordisk.com
                                         <mailto:krop@novonordisk.com>


 In North America:                       In North America:

 Sean Clements                           Hans Rommer

 Tel: (+1) 609 514 8316                  Tel: (+1) 609 919 7937

 secl@novonordisk.com                    hrmm@novonordisk.com
 <mailto:secl@novonordisk.com>           <mailto:hrmm@novonordisk.com>


Company Announcement no 1 / 2010



[HUG#1369894]





    Company Announcement  no 1 2010: 

http://hugin.info/2013/R/1369894/335032.pdf